Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
184 shown of 9,507 total abstracts
  1. Abstract 18062026-04-01 · 19:00 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    L. Paz-Ares, S. Tolaney, E. Winer · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 11782026-04-01 · 20:00 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with TNBC
    E. Winer, C. Robert, G. Curigliano, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 18292026-04-02 · 21:15 CT · S406
    Quality of life outcomes with Trodelvy in patients with TNBC
    A. Spira, G. Curigliano, N. Rizvi · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 19392026-04-02 · 19:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-150 study)
    M.C. Garassino, S. Antonia, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 19722026-04-02 · 15:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-40
    E. Winer, F. Andre · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 11662026-04-04 · 18:30 CT · S100A
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    C. Saura, N. Rizvi, R. Herbst, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 12362026-04-01 · 13:45 CT · Arie Crown Theater
    DESTINY-Breast-849: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    L. Paz-Ares, N. Rizvi, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 15872026-04-05 · 20:30 CT · S406
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-997
    H. Rugo, S. Peters, J. Cortes · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 17982026-04-02 · 19:30 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    H. Rugo, T. Mok · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 12482026-04-02 · 20:45 CT · S406
    MONALEESA-680: Kisqali (ribociclib) 2L in HR+ breast cancer
    A. Spira, T. Mok, M.C. Garassino, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 13262026-04-04 · 19:00 CT · Hall B1
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-529
    L. Paz-Ares, C. Saura, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 12292026-04-03 · 18:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-925 study)
    R. Herbst, J. Brahmer, A. Spira, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 11932026-04-01 · 14:30 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-291 study)
    A. Spira, F. Andre, S. Peters, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 18592026-04-01 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-838 study)
    A. Spira, H. Borghaei · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 14822026-04-05 · 18:15 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-664
    E. Winer, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 11892026-04-04 · 14:30 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-205 study)
    S. Antonia, M.C. Garassino, S. Modi, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 12102026-04-02 · 19:45 CT · S100A
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-85
    T. Mok, N. Rizvi, H. Borghaei · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 14812026-04-02 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-901 study)
    J. Brahmer, S. Antonia, M. Reck · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 18332026-04-02 · 18:45 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    S. Antonia, J. Cortes, J. Brahmer, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 14812026-04-04 · 15:30 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Tolaney, G. Curigliano, M. Krop, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 19832026-04-03 · 18:30 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-653 study)
    H. Borghaei, M. Reck, S. Peters, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 15982026-04-01 · 19:00 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    F. Andre, S. Peters, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 19412026-04-04 · 20:45 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Tolaney, G. Curigliano, H. Rugo, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 13312026-04-04 · 19:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-739
    H. Rugo, T. Mok · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 10462026-04-05 · 14:00 CT · Hall B1
    OlympiA-626: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    P. Schmid, H. Rugo, G. Curigliano, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 18062026-04-01 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-48
    H. Borghaei, S. Modi, M.C. Garassino, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 14062026-04-01 · 15:00 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    M. Krop, M. Reck · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 10702026-04-04 · 16:15 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-475
    S. Modi, G. Curigliano · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 11102026-04-04 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-399 study)
    H. Borghaei, N. Rizvi, A. Spira, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 17892026-04-03 · 19:30 CT · S100A
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-802
    C. Saura, P. Schmid · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 12452026-04-04 · 14:30 CT · S406
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-610
    M. Reck, M. Krop · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 16172026-04-05 · 21:45 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M.C. Garassino, R. Herbst, T. Mok, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 16262026-04-03 · 14:30 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-408 study)
    G. Curigliano, P. Schmid, M. Reck, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 13242026-04-05 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-955 study)
    H. Rugo, H. Borghaei · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 13842026-04-02 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-496 study)
    F. Andre, L. Paz-Ares, R. Herbst · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 15552026-04-05 · 15:15 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-627
    L. Paz-Ares, G. Curigliano · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 14512026-04-02 · 18:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-986
    S. Peters, N. Rizvi, P. Schmid · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 11752026-04-04 · 15:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-261 study)
    R. Herbst, E. Winer, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 14542026-04-05 · 14:30 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    M. Reck, C. Robert, H. Borghaei, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 19242026-04-02 · 20:45 CT · S406
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-631
    G. Curigliano, S. Antonia, C. Saura · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 14582026-04-03 · 13:45 CT · E450
    DESTINY-Breast-802: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    H. Borghaei, S. Antonia · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 18412026-04-04 · 15:15 CT · E450
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-796
    M.C. Garassino, T. Mok, H. Borghaei, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 18942026-04-01 · 14:15 CT · S406
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-589 study)
    F. Andre, M. Krop, T. Mok, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 11122026-04-03 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-417
    E. Winer, A. Spira, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 15852026-04-04 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-739 study)
    R. Herbst, N. Rizvi, J. Cortes, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 15152026-04-03 · 15:15 CT · E450
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-564
    M.C. Garassino, T. Mok, N. Rizvi, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 10252026-04-02 · 19:45 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-536 study)
    H. Rugo, J. Cortes · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 14362026-04-03 · 13:15 CT · S406
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-201
    H. Borghaei, T. Mok, G. Curigliano · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 13292026-04-01 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-325 study)
    P. Schmid, S. Tolaney, J. Brahmer · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 11832026-04-04 · 14:15 CT · Arie Crown Theater
    MONARCH-533: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    C. Saura, M. Reck, N. Rizvi · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 11072026-04-04 · 21:45 CT · E450
    DESTINY-Breast-652: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    S. Tolaney, M.C. Garassino · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 14182026-04-05 · 16:45 CT · S406
    Long-term follow-up of Keytruda 3L+ for TNBC: KEYNOTE-240
    L. Paz-Ares, S. Peters, G. Curigliano, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 17892026-04-04 · 19:30 CT · E450
    IMpower-769: Tecentriq (atezolizumab) maintenance in TNBC
    M. Reck, F. Andre, M. Krop, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 18732026-04-04 · 19:45 CT · Hall B1
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-596
    S. Modi, M. Reck, C. Saura, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 13892026-04-04 · 19:15 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-678
    S. Antonia, J. Brahmer, J. Cortes · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 11952026-04-03 · 16:00 CT · E450
    MONARCH-863: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    J. Cortes, F. Andre · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 13422026-04-02 · 15:30 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-41
    R. Herbst, G. Curigliano, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 19342026-04-04 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-31 study)
    R. Herbst, M. Krop, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 12832026-04-05 · 14:15 CT · E450
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-35 study)
    H. Borghaei, J. Brahmer · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 13292026-04-01 · 13:45 CT · S100A
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-104
    J. Cortes, A. Spira, S. Tolaney · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 14262026-04-03 · 15:45 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-378
    M. Reck, L. Paz-Ares, H. Rugo, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 11242026-04-01 · 15:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-476 study)
    N. Rizvi, H. Rugo, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 12232026-04-01 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-385
    F. Andre, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 13482026-04-05 · 19:00 CT · E450
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-884
    M.C. Garassino, J. Brahmer, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 11692026-04-05 · 14:45 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-284
    A. Spira, F. Andre, C. Robert, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 11592026-04-03 · 16:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-256
    M. Reck, A. Spira, H. Rugo, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 12952026-04-01 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-110 study)
    E. Winer, T. Mok, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 11012026-04-03 · 20:30 CT · Hall B1
    DESTINY-Breast-247: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    M. Krop, F. Andre · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 16392026-04-02 · 18:45 CT · S100A
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-310
    H. Rugo, P. Schmid, G. Curigliano, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 19232026-04-05 · 21:30 CT · Arie Crown Theater
    MONALEESA-272: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    J. Brahmer, H. Borghaei, R. Herbst · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract 17812026-04-01 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-233 study)
    C. Robert, M.C. Garassino, G. Curigliano · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 18142026-04-04 · 16:00 CT · E450
    PALOMA-464: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    C. Saura, F. Andre, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  73. Abstract 15842026-04-05 · 19:15 CT · S406
    PALOMA-26: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    M.C. Garassino, M. Krop, M. Reck, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 14442026-04-04 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-588 study)
    H. Borghaei, G. Curigliano, F. Andre, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 12372026-04-02 · 20:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-786
    M. Reck, S. Peters, L. Paz-Ares, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 14222026-04-03 · 14:00 CT · Hall B1
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-263
    J. Cortes, N. Rizvi, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 18122026-04-05 · 20:15 CT · S406
    MONARCH-649: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    A. Spira, H. Borghaei, S. Peters, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 17082026-04-02 · 21:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-318
    L. Paz-Ares, R. Herbst, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 17592026-04-04 · 14:00 CT · S406
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-785
    C. Saura, F. Andre, J. Cortes, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 17612026-04-02 · 16:45 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-143
    C. Saura, M.C. Garassino, J. Brahmer · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 10492026-04-03 · 18:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-470
    J. Brahmer, S. Modi, S. Tolaney · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 19122026-04-03 · 14:30 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-601
    S. Tolaney, R. Herbst, M.C. Garassino, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 12502026-04-02 · 14:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with TNBC
    M. Reck, S. Modi · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 16672026-04-04 · 15:45 CT · S100A
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-893
    H. Borghaei, M. Krop · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 11302026-04-04 · 15:00 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-476
    S. Modi, S. Antonia, N. Rizvi, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 10322026-04-05 · 16:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-324
    J. Cortes, M. Krop, T. Mok, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 13812026-04-01 · 13:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-494 study)
    N. Rizvi, P. Schmid · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 14202026-04-02 · 21:00 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-716
    P. Schmid, S. Antonia, S. Modi · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 19202026-04-03 · 15:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-663 study)
    M. Krop, M. Reck, F. Andre, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 10442026-04-05 · 20:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-941 study)
    A. Spira, F. Andre, P. Schmid · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 19722026-04-04 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-280 study)
    M.C. Garassino, A. Spira, E. Winer · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 10802026-04-04 · 18:30 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-983
    N. Rizvi, S. Peters, M. Krop · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 13272026-04-04 · 21:15 CT · S100A
    IMpower-371: Tecentriq (atezolizumab) neoadjuvant in TNBC
    C. Robert, H. Rugo, A. Spira, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 11372026-04-02 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-381
    R. Herbst, G. Curigliano, C. Saura, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 13022026-04-02 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-616 study)
    T. Mok, H. Rugo, H. Borghaei, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 16072026-04-03 · 18:00 CT · Hall B1
    MONALEESA-10: Kisqali (ribociclib) 2L in HR+ breast cancer
    A. Spira, H. Borghaei, M.C. Garassino · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 13642026-04-05 · 21:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-913 study)
    M.C. Garassino, C. Robert, P. Schmid · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 15652026-04-02 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-303 study)
    L. Paz-Ares, F. Andre · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 12952026-04-02 · 18:30 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-567
    N. Rizvi, S. Antonia · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 13272026-04-05 · 16:15 CT · E450
    MONARCH-384: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    S. Antonia, S. Modi, A. Spira, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 11852026-04-01 · 16:00 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    P. Schmid, J. Brahmer, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 13012026-04-05 · 19:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-132
    F. Andre, M. Krop, T. Mok · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 17772026-04-03 · 16:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-865 study)
    M. Krop, H. Rugo, P. Schmid · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 13372026-04-01 · 21:30 CT · S406
    PALOMA-824: Ibrance (palbociclib) maintenance in HR+ breast cancer
    A. Spira, M. Reck, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 19992026-04-05 · 20:45 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-880
    J. Brahmer, C. Robert, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 18272026-04-01 · 18:00 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-599
    M.C. Garassino, G. Curigliano, S. Antonia · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 19162026-04-02 · 13:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-627 study)
    M.C. Garassino, J. Brahmer · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 19142026-04-04 · 16:45 CT · Hall B1
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-300
    H. Borghaei, C. Robert, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 12382026-04-05 · 18:45 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-732
    P. Schmid, H. Rugo · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 14482026-04-03 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-789 study)
    J. Cortes, F. Andre · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 18962026-04-03 · 21:00 CT · E450
    MONARCH-353: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    R. Herbst, S. Modi, C. Saura, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 10372026-04-01 · 16:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-561
    H. Borghaei, S. Modi, N. Rizvi, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 15872026-04-03 · 19:15 CT · E450
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-192
    H. Borghaei, E. Winer, C. Robert · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 13252026-04-01 · 19:30 CT · S100A
    Long-term follow-up of Tecentriq 2L for TNBC: IMpower-881
    A. Spira, F. Andre, E. Winer, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 14892026-04-04 · 14:15 CT · S406
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-646
    S. Peters, T. Mok, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 15432026-04-01 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-129 study)
    T. Mok, M. Reck · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 18842026-04-01 · 19:45 CT · E450
    PALOMA-889: Ibrance (palbociclib) maintenance in HR+ breast cancer
    M.C. Garassino, L. Paz-Ares · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 16462026-04-04 · 21:30 CT · S406
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-446
    F. Andre, J. Brahmer, H. Borghaei, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  119. Abstract 18962026-04-01 · 18:45 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-126
    L. Paz-Ares, F. Andre, H. Rugo · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 16432026-04-05 · 13:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-228 study)
    J. Cortes, M. Reck, P. Schmid · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 15872026-04-03 · 19:15 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-980
    A. Spira, H. Rugo, F. Andre, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 16952026-04-05 · 19:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-223 study)
    S. Peters, M. Krop, E. Winer, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  123. Abstract 17132026-04-01 · 19:45 CT · Hall B1
    MONALEESA-508: Kisqali (ribociclib) 1L in HR+ breast cancer
    P. Schmid, M.C. Garassino, M. Reck · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 10072026-04-01 · 19:00 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-50
    G. Curigliano, S. Tolaney, P. Schmid, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 11792026-04-01 · 20:45 CT · S100A
    MONARCH-702: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    M. Krop, G. Curigliano, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 19072026-04-02 · 13:00 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-881 study)
    S. Tolaney, H. Rugo, L. Paz-Ares, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 10112026-04-03 · 13:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-653
    S. Modi, S. Peters, H. Borghaei, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 14422026-04-02 · 19:15 CT · Hall B1
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-777
    R. Herbst, T. Mok, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 16682026-04-05 · 19:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-245
    M.C. Garassino, E. Winer, F. Andre, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 17982026-04-04 · 18:30 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-471
    A. Spira, F. Andre, M. Krop · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 18742026-04-05 · 20:00 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    S. Antonia, G. Curigliano, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 12592026-04-04 · 19:00 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-846 study)
    M.C. Garassino, M. Reck · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 19962026-04-02 · 13:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-396
    J. Brahmer, P. Schmid · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 19912026-04-03 · 14:15 CT · Arie Crown Theater
    PALOMA-518: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    M. Reck, G. Curigliano · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 12282026-04-02 · 16:45 CT · E450
    MONALEESA-765: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    S. Antonia, H. Rugo · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 16102026-04-03 · 20:00 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-778
    T. Mok, H. Rugo · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  137. Abstract 16502026-04-01 · 15:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-84 study)
    T. Mok, R. Herbst, S. Tolaney · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 17512026-04-02 · 13:00 CT · Arie Crown Theater
    PALOMA-298: Ibrance (palbociclib) 1L in HR+ breast cancer
    M. Reck, S. Tolaney, M.C. Garassino · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 13462026-04-04 · 13:30 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-739
    F. Andre, C. Saura, T. Mok, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 15212026-04-03 · 19:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-750 study)
    S. Antonia, A. Spira, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 16482026-04-02 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-621 study)
    A. Spira, T. Mok, P. Schmid · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 15962026-04-01 · 18:45 CT · S100A
    MONALEESA-714: Kisqali (ribociclib) 1L in HR+ breast cancer
    N. Rizvi, G. Curigliano, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  143. Abstract 19072026-04-03 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-350 study)
    S. Antonia, S. Peters, A. Spira · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 14282026-04-04 · 19:15 CT · S406
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-935
    S. Peters, C. Robert, F. Andre · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract 11352026-04-01 · 19:00 CT · E450
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-458
    M.C. Garassino, F. Andre, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 16052026-04-04 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-102
    A. Spira, R. Herbst, S. Peters, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract 11232026-04-04 · 20:15 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-242
    H. Borghaei, C. Robert · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 18762026-04-02 · 18:45 CT · S100A
    MONARCH-543: Verzenio (abemaciclib) 1L in HR+ breast cancer
    P. Schmid, E. Winer · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 13822026-04-03 · 20:00 CT · Hall B1
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-660
    E. Winer, S. Peters, C. Saura · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 16112026-04-03 · 21:00 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-783
    N. Rizvi, A. Spira, E. Winer, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 15992026-04-05 · 19:30 CT · S406
    MONARCH-981: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    E. Winer, C. Saura, N. Rizvi, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 19702026-04-05 · 14:30 CT · S100A
    MONARCH-93: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    J. Brahmer, N. Rizvi, G. Curigliano · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 16832026-04-01 · 15:15 CT · S406
    MONALEESA-54: Kisqali (ribociclib) 1L in HR+ breast cancer
    H. Borghaei, F. Andre · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  154. Abstract 10732026-04-03 · 20:30 CT · S406
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-406
    E. Winer, M. Krop, J. Brahmer, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 10472026-04-04 · 18:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-256 study)
    P. Schmid, S. Modi, M. Krop, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 11172026-04-04 · 13:00 CT · E450
    DESTINY-Breast-292: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    N. Rizvi, S. Peters, R. Herbst · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 14392026-04-02 · 15:30 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-820
    F. Andre, C. Saura, H. Borghaei, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 13682026-04-01 · 21:45 CT · S406
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-991
    C. Robert, L. Paz-Ares, M. Krop, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 17502026-04-04 · 19:00 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-201
    C. Saura, P. Schmid · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 14372026-04-02 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-6 study)
    H. Borghaei, M. Krop, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 13942026-04-03 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-266 study)
    C. Saura, P. Schmid, R. Herbst, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 13582026-04-02 · 16:00 CT · Hall B1
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-883
    L. Paz-Ares, R. Herbst, H. Rugo, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 11392026-04-05 · 19:15 CT · Hall B1
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-480
    E. Winer, M.C. Garassino, F. Andre, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 12102026-04-01 · 15:00 CT · S406
    MONALEESA-935: Kisqali (ribociclib) 1L in HR+ breast cancer
    C. Saura, F. Andre · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 12182026-04-04 · 20:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-199 study)
    F. Andre, A. Spira, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 15032026-04-05 · 20:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-228
    F. Andre, M. Reck, M.C. Garassino, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 18512026-04-01 · 18:15 CT · S100A
    PALOMA-534: Ibrance (palbociclib) maintenance in HR+ breast cancer
    H. Borghaei, P. Schmid, H. Rugo, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 11372026-04-04 · 13:45 CT · S100A
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-402
    P. Schmid, H. Borghaei · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 19712026-04-04 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-567
    C. Saura, J. Cortes · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 19962026-04-01 · 18:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-106 study)
    A. Spira, E. Winer · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 13482026-04-03 · 19:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-135 study)
    F. Andre, L. Paz-Ares · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 14952026-04-01 · 21:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-486 study)
    J. Brahmer, R. Herbst · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 13012026-04-01 · 13:15 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-394
    A. Spira, E. Winer, J. Cortes · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 14012026-04-01 · 21:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-84
    A. Spira, L. Paz-Ares, H. Borghaei, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 13722026-04-01 · 15:15 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    F. Andre, S. Antonia, C. Saura, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 15252026-04-04 · 16:45 CT · S406
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-727
    J. Brahmer, C. Robert, N. Rizvi · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 18612026-04-05 · 18:00 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-156
    S. Modi, J. Brahmer · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 18052026-04-03 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-559 study)
    S. Modi, S. Peters, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 16522026-04-05 · 21:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-326
    S. Modi, P. Schmid · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 17012026-04-01 · 21:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-973
    T. Mok, L. Paz-Ares, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 13812026-04-03 · 13:30 CT · E450
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-441
    R. Herbst, H. Borghaei, M.C. Garassino · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 13892026-04-03 · 15:00 CT · E450
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-552
    R. Herbst, C. Saura, T. Mok, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 14022026-04-05 · 18:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-241 study)
    R. Herbst, J. Cortes, F. Andre, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  184. Abstract 10542026-04-01 · 14:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-401 study)
    J. Brahmer, S. Tolaney, M. Reck · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.